European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2025
Electrochemotherapy for cutaneous Kaposi Sarcoma: A European register-based cohort study from the International Network for Sharing Practices of electrochemotherapy (InspECT).
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quaglino Pietro, Brizio Matteo, Bertino Giulia, Kis Erika, Mascherini Matteo, Battista Michela, Kunte Christian, Mowatt David, Russano Francesco, Giorgione Roberto, Clover A James P, Minuti Marta, Schepler Hadrian, Fabrizio Tommaso, Tauceri Francesca, Bonadies Antonio, Sersa Gregor, Odili Joy
Аннотация
INTRODUCTION: Kaposi sarcoma (KS) is a cancer of endothelial cells involving the skin and visceral organs. Electrochemotherapy (ECT) is an alternative treatment option for patients with cutaneous malignancies of skin and non-skin origin not suitable for conventional treatments. ECT exerts anti-tumour activity through enhanced drug delivery to tumour cells and cytotoxicity, inducing immunogenic tumour cell death and through a vascular-disrupting effect.
MATERIALS AND METHODS: In this multi-institutional prospective, observational study, we aimed to evaluate the outcomes of using ECT as a treatment modality for cutaneous Kaposi's Sarcoma within the InspECT (International Network for Sharing Practice on ECT) registry. Patients with superficial lesions of Kaposi Sarcoma from 19 European centres were included. They underwent at least one ECT session with bleomycin performed following the European Standard Operating Procedures, between March 2011 and June 2024.
RESULTS: The analysis included 82 patients (mean age 71 years; median number of lesions/patient 2). Side effects were reported as mild and easily manageable. The response to treatment per patient was 80 % complete and 13 % partial. In the multivariate model, time since diagnosis to ECT and small tumour size showed a significant association with a complete response. One-year local progression-free survival (LPFS) in the whole population was 93 %, 2 years LPFS was 89 %.
CONCLUSIONS: In the present study, ECT showed antitumor activity and a favourable safety profile in patients with cutaneous Kaposi Sarcoma either not suitable for conventional treatments or that refused them. Better results were obtained in small tumours (<3 cm) using hexagonal electrodes.
MATERIALS AND METHODS: In this multi-institutional prospective, observational study, we aimed to evaluate the outcomes of using ECT as a treatment modality for cutaneous Kaposi's Sarcoma within the InspECT (International Network for Sharing Practice on ECT) registry. Patients with superficial lesions of Kaposi Sarcoma from 19 European centres were included. They underwent at least one ECT session with bleomycin performed following the European Standard Operating Procedures, between March 2011 and June 2024.
RESULTS: The analysis included 82 patients (mean age 71 years; median number of lesions/patient 2). Side effects were reported as mild and easily manageable. The response to treatment per patient was 80 % complete and 13 % partial. In the multivariate model, time since diagnosis to ECT and small tumour size showed a significant association with a complete response. One-year local progression-free survival (LPFS) in the whole population was 93 %, 2 years LPFS was 89 %.
CONCLUSIONS: In the present study, ECT showed antitumor activity and a favourable safety profile in patients with cutaneous Kaposi Sarcoma either not suitable for conventional treatments or that refused them. Better results were obtained in small tumours (<3 cm) using hexagonal electrodes.